Bipolar Disorder (Manic Depression) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Bipolar Disorder (Manic Depression) – Drugs In Development, 2024 report and make more profitable business decisions.
Bipolar disorder, previously known as manic depression, is a mental health condition characterized by extreme mood swings that include emotional highs (mania or hypomania) and lows (depression). These mood shifts can significantly impact a person’s ability to function in daily life. The exact cause of bipolar disorder is not fully understood, but it is believed to involve a combination of genetic, biological, and environmental factors. Stressful life events or disruptions in neurotransmitter function in the brain may also contribute to the onset of symptoms.
The Bipolar Disorder (Manic Depression) drugs in development market research report provide comprehensive information on the therapeutics under development for Bipolar Disorder (Manic Depression), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bipolar Disorder (Manic Depression) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Bipolar Disorder (Manic Depression) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 59 molecules, with 55 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Bipolar Disorder (Manic Depression) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Bipolar Disorder (Manic Depression) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Bipolar Disorder (Manic Depression) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
4M Therapeutics IncAbbVie Inc
Adare Pharma Solutions
Alzamend Neuro Inc
Amorsa Therapeutics Inc
Ben-Gurion University of the Negev
Benuvia Therapeutics Inc
Biohaven Ltd
BioXcel Therapeutics Inc
Blue Oak Pharmaceuticals Inc
Cellix Bio Pvt Ltd
Celon Pharma SA
Cerevel Therapeutics Holdings Inc
Delpor Inc
Engrail Therapeutics Inc
Entheogenix Biosciences Inc
Epinogen Co Ltd
Gerbera Therapeutics Ltd
GH Research PLC
H. Lundbeck AS
Iltoo Pharma
Intra-Cellular Therapies Inc
Jina Pharmaceuticals Inc
Johnson & Johnson
Luye Pharma Group Ltd
Lyndra Therapeutics Inc.
Mental-Heal Ltd
National Institute of Neurological Disorders and Stroke
Neonc Technologies Inc
Neumora Therapeutics Inc
Neurelis Inc
Neurocentrx Pharma Ltd
Neurocyte Therapeutics Inc
NRX Pharmaceuticals Inc
Omeros Corp
Otsuka Pharmaceutical Co Ltd
OWP Pharmaceuticals Inc
Pasithea Therapeutics Corp
PharmaMax Corp
PharmaTher Holdings Ltd
Qilu Pharmaceutical Co Ltd
Reviva Pharmaceuticals Inc
RIKEN
Sage Therapeutics Inc
Saniona AB
SK Life Science Inc
Sound Pharmaceuticals Inc
Sumitomo Pharma Co Ltd
Suven Life Sciences Ltd
Tonix Pharmaceuticals Holding Corp
U.S. National Institutes of Health
Unravel Biosciences
Vanda Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Bipolar Disorder (Manic Depression) reports